Health
Nanoparticle based shot could boost efficacy, accelerate production of seasonal flu vaccines – BioPharma-Reporter.com
Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC). An experimental recombinant protein…
Key to the vaccine’s success is a liposome the developers created called cobalt-porphyrin-phospholipid, or CoPoP. They are tiny spherical sacs, which are small enough to be considered nanoparticles, and they form the backbone of the vaccine platform.
Described in a study published on May 24 by the Proceedings of the National Academy of Science, the experimental vaccine has reportedly proven effective in preclinical studies.
The results are very encouraging, says the study’s senior author, Jonathan…
-
Business21 hours agoBroker names 2 small cap ASX shares to buy for big returns
-
Business21 hours agoThese top ASX 200 stocks could rise 25% to 60%
-
Noosa News21 hours agoMin Woo Lee, Adam Scott and Cameron Smith in the mix after Australian PGA opening round in Brisbane
-
Noosa News21 hours agoDid AI write your accounting expert’s report? – Proctor